PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 29608014-0 2018 Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype. phyllodes 68-77 integrin linked kinase Homo sapiens 27-49 32116328-4 2020 By contrast, canalicular carcinoma (Grades I and IIB) and phyllodes tumors had very low expression levels of BIK. phyllodes 58-67 BCL2 interacting killer Homo sapiens 109-112 30383904-0 2019 Expression of biomarkers in the AKT pathway correlates with malignancy and recurrence in phyllodes tumours of the breast. phyllodes 89-98 AKT serine/threonine kinase 1 Homo sapiens 32-35 31192133-1 2019 Purpose: To determine the potential of mammography (MG) and mammographic texture analysis in differentiation between Grade 1 (G1) and Grade 2/ Grade 3 (G2/G3) phyllodes tumors (PTs) of breast. phyllodes 159-168 crystallin gamma E, pseudogene Homo sapiens 117-157 30486739-3 2018 This work was undertaken to evaluate the expression of B7-H3 and B7-H4 in phyllodes tumors and assess the association with the grade and clinical behavior of phyllodes tumors. phyllodes 74-83 CD276 antigen Mus musculus 55-60 30486739-7 2018 B7-H3 messenger RNA and protein appeared to be concentrated mainly in the stromal compartment of phyllodes tumors. phyllodes 97-106 CD276 antigen Mus musculus 0-5 30486739-9 2018 Stromal B7-H3 messenger RNA and protein expression were noted in 10 (16.7%) and 31 (51.7%) of 60 benign phyllodes tumors, 12 (46.1%) and 20 (76.9%) of 26 borderline phyllodes tumors, and 10 (66.7%) and 13 (86.7%) of 15 malignant phyllodes tumors, respectively. phyllodes 104-113 CD276 antigen Mus musculus 8-13 30486739-9 2018 Stromal B7-H3 messenger RNA and protein expression were noted in 10 (16.7%) and 31 (51.7%) of 60 benign phyllodes tumors, 12 (46.1%) and 20 (76.9%) of 26 borderline phyllodes tumors, and 10 (66.7%) and 13 (86.7%) of 15 malignant phyllodes tumors, respectively. phyllodes 165-174 CD276 antigen Mus musculus 8-13 30486739-9 2018 Stromal B7-H3 messenger RNA and protein expression were noted in 10 (16.7%) and 31 (51.7%) of 60 benign phyllodes tumors, 12 (46.1%) and 20 (76.9%) of 26 borderline phyllodes tumors, and 10 (66.7%) and 13 (86.7%) of 15 malignant phyllodes tumors, respectively. phyllodes 165-174 CD276 antigen Mus musculus 8-13 30486739-10 2018 Stromal B7-H3 messenger RNA and protein expression increased as phyllodes tumors progressed from benign to borderline and finally to the malignant grade (Pearson"s R = 0.411, p < 0.001 and Pearson"s R = 0.293, p = 0.003, respectively). phyllodes 64-73 CD276 antigen Mus musculus 8-13 30486739-13 2018 These results suggest that B7-H3 is involved in the progression of phyllodes tumors and may contribute to their immune surveillance. phyllodes 67-76 CD276 antigen Mus musculus 27-32 29608014-0 2018 Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype. phyllodes 68-77 integrin linked kinase Homo sapiens 51-54 29608014-0 2018 Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype. phyllodes 68-77 zinc finger E-box binding homeobox 1 Homo sapiens 60-64 29608014-4 2018 In this study, we aimed to investigate ILK and EMT markers expression in phyllodes breast tumors in relation to tumor grade. phyllodes 73-82 integrin linked kinase Homo sapiens 39-42 28968268-7 2018 Focal expression (5% of the tumor cells) of cytokeratin cocktail and p63 was identified in the stroma of 2 of 10 malignant phyllodes tumors in a scattered/patchy pattern. phyllodes 123-132 tumor protein p63 Homo sapiens 69-72 29043292-2 2017 TERT promoter hotspot mutations have been documented in phyllodes tumors, and found to be more frequent in borderline and malignant lesions. phyllodes 56-65 telomerase reverse transcriptase Homo sapiens 0-4 29315289-1 2018 BACKGROUND: MED12 and TERT promoter mutations have been shown to be the most common somatic mutations in phyllodes tumours (PTs). phyllodes 105-114 mediator complex subunit 12 Homo sapiens 12-17 29315289-1 2018 BACKGROUND: MED12 and TERT promoter mutations have been shown to be the most common somatic mutations in phyllodes tumours (PTs). phyllodes 105-114 telomerase reverse transcriptase Homo sapiens 22-26 28380418-8 2017 These findings show that expression of EMT markers, the mode of surgical management, and a history of recent tumor growth had prognostic potential for patients with phyllodes tumors of the breast. phyllodes 165-174 IL2 inducible T cell kinase Homo sapiens 39-42 28029685-11 2017 CD34 (a marker often positive in phyllodes tumours) is consistently negative in MBC. phyllodes 33-42 CD34 molecule Homo sapiens 0-4 27806318-1 2016 Exome sequencing has recently identified highly recurrent MED12 somatic mutations in fibroadenomas (FAs) and phyllodes tumors (PTs). phyllodes 109-118 mediator complex subunit 12 Homo sapiens 58-63 27806318-3 2016 We show that MED12 mutations are associated with benign behavior of phyllodes tumors, as they are detected less frequently in malignant PTs (27.6%) compared to benign (58.3%) and borderline (63.3%) PTs, respectively (p = 0.0036). phyllodes 68-77 mediator complex subunit 12 Homo sapiens 13-18 27806318-4 2016 Phyllodes tumors presented marked temporal heterogeneity of MED12 mutation status, as 50% (3/6) of primary and recurrent phyllodes tumor pairs with MED12 mutation presented different MED12 mutations between the primary and recurrent tumors. phyllodes 0-9 mediator complex subunit 12 Homo sapiens 60-65 27806318-4 2016 Phyllodes tumors presented marked temporal heterogeneity of MED12 mutation status, as 50% (3/6) of primary and recurrent phyllodes tumor pairs with MED12 mutation presented different MED12 mutations between the primary and recurrent tumors. phyllodes 0-9 mediator complex subunit 12 Homo sapiens 148-153 27806318-4 2016 Phyllodes tumors presented marked temporal heterogeneity of MED12 mutation status, as 50% (3/6) of primary and recurrent phyllodes tumor pairs with MED12 mutation presented different MED12 mutations between the primary and recurrent tumors. phyllodes 0-9 mediator complex subunit 12 Homo sapiens 148-153 25855048-2 2015 The aim of this study was to define whether phyllodes tumours (PTs) would harbour MED12 somatic mutations in a way akin to FAs. phyllodes 44-53 mediator complex subunit 12 Homo sapiens 82-87 27056456-10 2016 Epithelial expression of ERalpha was significantly higher in fibroadenomas (p<0.001) than in phyllodes tumours. phyllodes 96-105 estrogen receptor 1 Homo sapiens 25-32 27056456-11 2016 Conversely, both epithelial and stromal expression of ERbeta was significantly higher in phyllodes tumours (p<0.001). phyllodes 89-98 estrogen receptor 2 Homo sapiens 54-60 27290698-0 2016 Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression. phyllodes 17-26 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 65-69 26856273-0 2016 Frequency of MED12 mutations in phyllodes tumors: Inverse correlation with histologic grade. phyllodes 32-41 mediator complex subunit 12 Homo sapiens 13-18 26625196-10 2016 Overexpression of molecular biomarkers of increased angiogenesis, EGFR and immune checkpoints provides novel targeted therapy options in malignant phyllodes tumors of the breast. phyllodes 147-156 epidermal growth factor receptor Homo sapiens 66-70 28066593-1 2016 BACKGROUND: A retrospective analysis of diagnoses was performed in patients with phyllodes tumors of the breast (PTB) who received preoperative core needle biopsy (CNB) and had breast surgery at Fudan University Shanghai Cancer Center from January 1, 2002 to April 1, 2013. phyllodes 81-90 polypyrimidine tract binding protein 1 Homo sapiens 113-116 27628602-9 2016 We conclude from these findings that the hypoglycemic attack was related to the elevated IGF-II level in the giant phyllodes tumor of the breast. phyllodes 115-124 insulin like growth factor 2 Homo sapiens 89-95 26961242-6 2016 We aimed to develop a practical molecular test to aid in distinguishing fibroadenomas from phyllodes tumors in the pre-operative setting. phyllodes 91-100 activation induced cytidine deaminase Homo sapiens 50-53 26676988-0 2016 Loss of imprinting of IGF2 in fibroadenomas and phyllodes tumors of the breast. phyllodes 48-57 insulin like growth factor 2 Homo sapiens 22-26 26773878-10 2016 This is the first case of phyllodes tumor rapidly enlarging during anti-HER2 chemotherapy for locally advanced HER2-positive breast cancer. phyllodes 26-35 erb-b2 receptor tyrosine kinase 2 Homo sapiens 72-76 26773878-10 2016 This is the first case of phyllodes tumor rapidly enlarging during anti-HER2 chemotherapy for locally advanced HER2-positive breast cancer. phyllodes 26-35 erb-b2 receptor tyrosine kinase 2 Homo sapiens 111-115 26355235-0 2015 TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast. phyllodes 82-91 telomerase reverse transcriptase Homo sapiens 0-4 26437033-5 2015 Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development. phyllodes 8-17 filamin A Homo sapiens 48-52 26437033-5 2015 Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development. phyllodes 8-17 SET domain containing 2, histone lysine methyltransferase Homo sapiens 54-59 26437033-5 2015 Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development. phyllodes 8-17 lysine methyltransferase 2D Homo sapiens 64-69 26437033-5 2015 Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development. phyllodes 100-109 filamin A Homo sapiens 48-52 26437033-5 2015 Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development. phyllodes 100-109 lysine methyltransferase 2D Homo sapiens 64-69 26355235-0 2015 TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast. phyllodes 82-91 mediator complex subunit 12 Homo sapiens 63-68 26355235-4 2015 RESULTS: Sequencing analyses showed that TERT promoter mutations were frequent in phyllodes tumors (30/46, 65%), but rare in fibroadenomas (4/58, 7%). phyllodes 82-91 telomerase reverse transcriptase Homo sapiens 41-45 26355235-9 2015 Because TERT promoter mutations are rare among fibroadenomas, their detection may be of potential use in discriminating between phyllodes tumors and fibroadenomas. phyllodes 128-137 telomerase reverse transcriptase Homo sapiens 8-12 25931199-9 2015 In conclusion, we confirm the frequent occurrence of MED12 mutations in fibroadenomas, provide evidence that most intracanalicular fibroadenomas closely resembling benign phyllodes as well as benign phyllodes tumors harbor MED12 mutations, and conclude that MED12 mutations in malignant phyllodes tumors appear to be relatively rare. phyllodes 171-180 mediator complex subunit 12 Homo sapiens 53-58 26056158-0 2015 Associations of epithelial c-kit expression in phyllodes tumours of the breast. phyllodes 47-56 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 27-32 25652050-1 2015 PURPOSE: To ensure a surgical margin of >=1 cm for the effective treatment of phyllodes tumors of the breast (PTB) a second resection has been recommended, but the outcomes of an extensive series of cases employing the aforementioned criterion cast doubt on this clinical approach. phyllodes 81-90 polypyrimidine tract binding protein 1 Homo sapiens 113-116 26018969-9 2015 CONCLUSIONS: Similar to fibroadenomas, phyllodes tumours show a high frequency of MED12 mutations, affirming the close biological relationship between these fibroepithelial neoplasms. phyllodes 39-48 mediator complex subunit 12 Homo sapiens 82-87 25865354-0 2015 MED12 exon 2 mutations in phyllodes tumors of the breast. phyllodes 26-35 mediator complex subunit 12 Homo sapiens 0-5 25839987-0 2015 Frequent MED12 mutations in phyllodes tumours of the breast. phyllodes 28-37 mediator complex subunit 12 Homo sapiens 9-14 25865354-3 2015 Here, we examined the MED12 mutation in phyllodes tumors, another biphasic tumor with epithelial and stromal components related to breast fibroadenomas. phyllodes 40-49 mediator complex subunit 12 Homo sapiens 22-27 25795733-9 2015 LamC2 and kalinin B1 each showed positive stromal cell expression in two of 20 (10%) phyllodes tumours. phyllodes 85-94 laminin subunit gamma 2 Homo sapiens 0-5 25839987-9 2015 CONCLUSIONS: MED12 mutations were frequent among the phyllodes tumours of the breast, regardless of the tumour grade. phyllodes 53-62 mediator complex subunit 12 Homo sapiens 13-18 24492332-1 2014 Adequate management of phyllodes tumors of the breast (PTB) remains a challenge because of the difficulty in correctly establishing preoperative diagnosis. phyllodes 23-32 polypyrimidine tract binding protein 1 Homo sapiens 55-58 25216225-3 2015 Reports of CD117 expression in phyllodes tumors have been controversial. phyllodes 31-40 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 11-16 24807638-1 2014 The purpose of this study is to investigate the expression of succinate dehydrogenase (SDH)A, SDHB, and HIF-1alpha in phyllodes tumors and the association with clinic-pathologic factors. phyllodes 118-127 succinate dehydrogenase complex iron sulfur subunit B Homo sapiens 87-90 24807638-1 2014 The purpose of this study is to investigate the expression of succinate dehydrogenase (SDH)A, SDHB, and HIF-1alpha in phyllodes tumors and the association with clinic-pathologic factors. phyllodes 118-127 succinate dehydrogenase complex iron sulfur subunit B Homo sapiens 94-98 24807638-1 2014 The purpose of this study is to investigate the expression of succinate dehydrogenase (SDH)A, SDHB, and HIF-1alpha in phyllodes tumors and the association with clinic-pathologic factors. phyllodes 118-127 hypoxia inducible factor 1 subunit alpha Homo sapiens 104-114 24807638-9 2014 In conclusion, Tumor grade is positively correlated with SDHA and SDHB expression in the tumor stroma in phyllodes tumors of the breast. phyllodes 105-114 succinate dehydrogenase complex flavoprotein subunit A Homo sapiens 57-61 24807638-9 2014 In conclusion, Tumor grade is positively correlated with SDHA and SDHB expression in the tumor stroma in phyllodes tumors of the breast. phyllodes 105-114 succinate dehydrogenase complex iron sulfur subunit B Homo sapiens 66-70 25593300-0 2015 Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors. phyllodes 91-100 mediator complex subunit 12 Homo sapiens 37-42 25677742-0 2015 Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast. phyllodes 89-98 twist family bHLH transcription factor 1 Homo sapiens 70-75 25677742-0 2015 Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast. phyllodes 89-98 forkhead box C2 Homo sapiens 80-85 25046342-0 2014 A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies. phyllodes 22-31 tumor protein p63 Homo sapiens 47-50 25046342-0 2014 A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies. phyllodes 22-31 tumor protein p63 Homo sapiens 55-58 25046342-8 2014 CD34 labeled 57% malignant phyllodes tumors and no sarcomatoid carcinomas. phyllodes 27-36 CD34 molecule Homo sapiens 0-4 25046342-10 2014 In the differential diagnosis of malignant phyllodes, p40 is a more specific but less sensitive marker of sarcomatoid carcinoma than p63. phyllodes 43-52 tumor protein p63 Homo sapiens 54-57 24961352-0 2014 Phyllodes tumor of the breast: role of Axl and ST6GalNAcII in the development of mammary phyllodes tumors. phyllodes 0-9 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 Homo sapiens 47-58 24961352-0 2014 Phyllodes tumor of the breast: role of Axl and ST6GalNAcII in the development of mammary phyllodes tumors. phyllodes 89-98 AXL receptor tyrosine kinase Homo sapiens 39-42 24961352-0 2014 Phyllodes tumor of the breast: role of Axl and ST6GalNAcII in the development of mammary phyllodes tumors. phyllodes 89-98 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 Homo sapiens 47-58 24961352-3 2014 The purpose of this study was to evaluate the implications of Axl and ST6GalNAcII in phyllodes tumors. phyllodes 85-94 AXL receptor tyrosine kinase Homo sapiens 62-65 24961352-3 2014 The purpose of this study was to evaluate the implications of Axl and ST6GalNAcII in phyllodes tumors. phyllodes 85-94 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 Homo sapiens 70-81 23895135-18 2013 CONCLUSIONS: We describe for the first time an NRAS mutation with concomitant activation of PI3K/Akt/mTOR in phyllodes tumor. phyllodes 109-118 NRAS proto-oncogene, GTPase Homo sapiens 47-51 24980553-5 2014 Microarray showed that miR-21 was one of the most significantly upregulated microRNAs in malignant phyllodes tumors compared with benign phyllodes tumors. phyllodes 99-108 microRNA 21 Homo sapiens 23-29 24980553-5 2014 Microarray showed that miR-21 was one of the most significantly upregulated microRNAs in malignant phyllodes tumors compared with benign phyllodes tumors. phyllodes 137-146 microRNA 21 Homo sapiens 23-29 24438019-3 2014 We aimed to investigate the expression and prognostic importance of Six1 and Pax3 homeoproteins in phyllodes tumours - a group of uncommon biphasic tumours comprising both epithelial and stromal components. phyllodes 99-108 SIX homeobox 1 Homo sapiens 68-72 24438019-3 2014 We aimed to investigate the expression and prognostic importance of Six1 and Pax3 homeoproteins in phyllodes tumours - a group of uncommon biphasic tumours comprising both epithelial and stromal components. phyllodes 99-108 paired box 3 Homo sapiens 77-81 23916291-0 2013 A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway. phyllodes 22-31 cyclin dependent kinase inhibitor 2A Homo sapiens 69-72 23916291-2 2013 Here, we systematically study p16 and Rb expression in 34 phyllodes tumors in relation to proliferation. phyllodes 58-67 cyclin dependent kinase inhibitor 2A Homo sapiens 30-33 23916291-8 2013 Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+). phyllodes 37-46 cyclin dependent kinase inhibitor 2A Homo sapiens 69-72 23916291-8 2013 Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+). phyllodes 37-46 cyclin dependent kinase inhibitor 2A Homo sapiens 123-126 23916291-8 2013 Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+). phyllodes 37-46 cyclin dependent kinase inhibitor 2A Homo sapiens 123-126 23916291-8 2013 Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+). phyllodes 37-46 cyclin dependent kinase inhibitor 2A Homo sapiens 123-126 23916291-13 2013 Ki-67 was highest in malignant phyllodes with diffuse p16+/Rb- labeling. phyllodes 31-40 cyclin dependent kinase inhibitor 2A Homo sapiens 54-57 23916291-14 2013 In summary, 50% malignant phyllodes display evidence of Rb/p16 pathway alterations, likely reflecting p16 or Rb inactivation. phyllodes 26-35 cyclin dependent kinase inhibitor 2A Homo sapiens 59-62 23916291-14 2013 In summary, 50% malignant phyllodes display evidence of Rb/p16 pathway alterations, likely reflecting p16 or Rb inactivation. phyllodes 26-35 cyclin dependent kinase inhibitor 2A Homo sapiens 102-105 23772632-4 2013 CD34, VEGF and beta-catenin in stromal cells were expressed, respectively, in: 38.3%, 29.2% and 27.5% of benign phyllodes tumours; 33.3%, 58.3% and 54.2% of borderline phyllodes tumours; and 5.9%, 64.7% and 76.5% of malignant phyllodes tumours; these associations with histological grade were statistically significant. phyllodes 112-121 CD34 molecule Homo sapiens 0-4 23772632-4 2013 CD34, VEGF and beta-catenin in stromal cells were expressed, respectively, in: 38.3%, 29.2% and 27.5% of benign phyllodes tumours; 33.3%, 58.3% and 54.2% of borderline phyllodes tumours; and 5.9%, 64.7% and 76.5% of malignant phyllodes tumours; these associations with histological grade were statistically significant. phyllodes 112-121 vascular endothelial growth factor A Homo sapiens 6-10 23772632-4 2013 CD34, VEGF and beta-catenin in stromal cells were expressed, respectively, in: 38.3%, 29.2% and 27.5% of benign phyllodes tumours; 33.3%, 58.3% and 54.2% of borderline phyllodes tumours; and 5.9%, 64.7% and 76.5% of malignant phyllodes tumours; these associations with histological grade were statistically significant. phyllodes 112-121 catenin beta 1 Homo sapiens 15-27 23772632-4 2013 CD34, VEGF and beta-catenin in stromal cells were expressed, respectively, in: 38.3%, 29.2% and 27.5% of benign phyllodes tumours; 33.3%, 58.3% and 54.2% of borderline phyllodes tumours; and 5.9%, 64.7% and 76.5% of malignant phyllodes tumours; these associations with histological grade were statistically significant. phyllodes 168-177 CD34 molecule Homo sapiens 0-4 23895135-18 2013 CONCLUSIONS: We describe for the first time an NRAS mutation with concomitant activation of PI3K/Akt/mTOR in phyllodes tumor. phyllodes 109-118 AKT serine/threonine kinase 1 Homo sapiens 97-100 23895135-18 2013 CONCLUSIONS: We describe for the first time an NRAS mutation with concomitant activation of PI3K/Akt/mTOR in phyllodes tumor. phyllodes 109-118 mechanistic target of rapamycin kinase Homo sapiens 101-105 23794094-0 2013 A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil. phyllodes 53-62 tumor protein p53 Homo sapiens 2-6 23794094-1 2013 A few studies have reported phyllodes tumors (PT) of the breast with germline TP53 mutations. phyllodes 28-37 tumor protein p53 Homo sapiens 78-82 22006372-4 2012 The purpose of this study was to evaluate the usefulness of immunohistochemical staining of stromal CD10 in predicting the likelihood of metastasis in phyllodes tumors. phyllodes 151-160 membrane metalloendopeptidase Homo sapiens 100-104 23150175-0 2013 Expression of TWIST1, Snail, Slug, and NF-kappaB and methylation of the TWIST1 promoter in mammary phyllodes tumor. phyllodes 99-108 twist family bHLH transcription factor 1 Homo sapiens 72-78 23291960-0 2013 Ubiquitin carboxy-terminal hydrolase L1 may be involved in the development of mammary phyllodes tumors. phyllodes 86-95 ubiquitin C-terminal hydrolase L1 Homo sapiens 0-39 22820000-0 2012 E-cadherin expression in the epithelial components of mammary phyllodes tumors. phyllodes 62-71 cadherin 1 Homo sapiens 0-10 22571452-0 2012 Involvement of alpha- and beta-catenins and E-cadherin in the development of mammary phyllodes tumours. phyllodes 85-94 cadherin 1 Homo sapiens 15-54 22006372-5 2012 METHODS: The expression of CD10 was studied in 43 phyllodes tumors (16 benign, 10 borderline, and 17 malignant) using immunohistochemistry to evaluate whether differences in expression correlated with the presence of, and or, development of distant metastasis. phyllodes 50-59 membrane metalloendopeptidase Homo sapiens 27-31 22006372-8 2012 CONCLUSIONS: The expression of CD10 can be used to predict the occurrence of distant metastasis in phyllodes tumors of the breast. phyllodes 99-108 membrane metalloendopeptidase Homo sapiens 31-35 21030860-5 2011 p53 and phospho-Histone3 (mitotic marker) showed increased staining in higher grade phyllodes tumors. phyllodes 84-93 tumor protein p53 Homo sapiens 0-3 22816226-24 2012 Stromal cells in phyllodes tumors are more PCNA positive than in fibroadenomas, also Ki-67 and androgen receptors are more positive in phyllodes tumors. phyllodes 17-26 proliferating cell nuclear antigen Homo sapiens 43-47 17158636-0 2007 Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. phyllodes 82-91 endothelin 1 Homo sapiens 0-12 20563638-13 2010 Elevated RASSF1A and/or TWIST1 methylation was significantly associated with phyllodes tumours compared with fibroadenomas (P = 0.02), TWIST1 methylation correlated with increasing malignancy in phyllodes tumours (P < 0.001). phyllodes 77-86 Ras association domain family member 1 Homo sapiens 9-16 20563638-13 2010 Elevated RASSF1A and/or TWIST1 methylation was significantly associated with phyllodes tumours compared with fibroadenomas (P = 0.02), TWIST1 methylation correlated with increasing malignancy in phyllodes tumours (P < 0.001). phyllodes 77-86 twist family bHLH transcription factor 1 Homo sapiens 24-30 20693983-0 2010 beta-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. phyllodes 80-89 catenin beta 1 Homo sapiens 0-12 19170049-2 2009 More recently, epithelial-stromal (ES) tumors resembling phyllodes tumors have been described in the seminal vesicles of TRAMP mice. phyllodes 57-66 tumor necrosis factor receptor superfamily, member 25 Mus musculus 121-126 18500266-1 2008 The expression of c-kit, a protooncogene tyrosine kinase receptor (CD117), in phyllodes tumors of the breast has been the subject of recent investigations. phyllodes 78-87 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 18-23 18500266-1 2008 The expression of c-kit, a protooncogene tyrosine kinase receptor (CD117), in phyllodes tumors of the breast has been the subject of recent investigations. phyllodes 78-87 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 67-72 20497245-0 2010 p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours. phyllodes 93-102 cyclin dependent kinase inhibitor 2A Homo sapiens 0-3 20497245-0 2010 p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours. phyllodes 93-102 RB transcriptional corepressor 1 Homo sapiens 8-11 16554735-10 2006 In conclusion, (i) only ER-beta is detected in the stroma of fibroadenomas and phyllodes tumors; (ii) its expression correlates with the expression of smooth muscle markers and suggests a role of ER-beta in myofibroblastic differentiation of stromal cells. phyllodes 79-88 estrogen receptor 2 Homo sapiens 24-31 16554735-0 2006 Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. phyllodes 73-82 estrogen receptor 2 Homo sapiens 0-22 16554735-6 2006 The highest percentage of ER-beta was observed in fibroadenomas with cellular stroma and in phyllodes tumors. phyllodes 92-101 estrogen receptor 2 Homo sapiens 26-33 16554735-9 2006 In contrast, in phyllodes tumors, ER-beta expression was higher in older patients. phyllodes 16-25 estrogen receptor 2 Homo sapiens 34-41 18032821-0 2007 Egfr amplification specific gene expression in phyllodes tumours of the breast. phyllodes 47-56 epidermal growth factor receptor Homo sapiens 0-4 18032821-2 2007 METHODS: In order to gain further insights into regulation mechanisms associated with egfr amplifications and EGFR expression in phyllodes tumours, we performed global gene expression analysis (Affymetrix A133.2) on a series of 10 phyllodes tumours, of these three with and seven without amplifications of an important regulatory repeat in intron 1 of egfr (CA-SSR I). phyllodes 129-138 epidermal growth factor receptor Homo sapiens 110-114 18032821-4 2007 RESULTS: We were able to show that the presence of egfr CA-SSR I amplifications in phyllodes tumours was associated with 230 differentially expressed genes. phyllodes 83-92 epidermal growth factor receptor Homo sapiens 51-55 16889904-0 2006 Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. phyllodes 99-108 tumor protein p53 Homo sapiens 15-18 16889904-0 2006 Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. phyllodes 99-108 MIB E3 ubiquitin protein ligase 1 Homo sapiens 23-28 16889904-9 2006 Positive staining for p53 was seen in 10 phyllodes tumors (24%), and the median MIB-1 index was 10%. phyllodes 41-50 tumor protein p53 Homo sapiens 22-25 15638374-5 2004 Our results show that Ki-67 and PCNA may be useful in the evaluation of stromal proliferation in phyllodes tumours (PT), which play an integral part in the progression from PTLGM through PTBM to PTHGM. phyllodes 97-106 proliferating cell nuclear antigen Homo sapiens 32-36 15917410-0 2005 Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. phyllodes 84-93 nitric oxide synthase 2 Homo sapiens 8-29 16168127-9 2005 Interestingly, concerted CAIX and HIF-1alpha expression was frequently found in morphologically normal epithelium of phyllodes tumors. phyllodes 117-126 carbonic anhydrase 9 Homo sapiens 25-29 16168127-9 2005 Interestingly, concerted CAIX and HIF-1alpha expression was frequently found in morphologically normal epithelium of phyllodes tumors. phyllodes 117-126 hypoxia inducible factor 1 subunit alpha Homo sapiens 34-44 16168127-12 2005 High expression of VEGF was regularly found in both tumors, with only a positive relation between stromal VEGF and grade in phyllodes tumors (P = 0.016). phyllodes 124-133 vascular endothelial growth factor A Homo sapiens 19-23 16168127-13 2005 Stromal HIF-1alpha overexpression in phyllodes tumors was predictive of disease-free survival (P = 0.032). phyllodes 37-46 hypoxia inducible factor 1 subunit alpha Homo sapiens 8-18 16168127-16 2005 In contrast, coexpression of HIF-1alpha and CAIX in the epithelium in phyllodes tumors points to epithelial hypoxia, most probably caused by relatively distant blood vessels. phyllodes 70-79 hypoxia inducible factor 1 subunit alpha Homo sapiens 29-39 16168127-16 2005 In contrast, coexpression of HIF-1alpha and CAIX in the epithelium in phyllodes tumors points to epithelial hypoxia, most probably caused by relatively distant blood vessels. phyllodes 70-79 carbonic anhydrase 9 Homo sapiens 44-48 15452163-6 2004 CONCLUSION: c-KIT expression is a frequent finding in phyllodes tumours, particularly in malignant cases; however, no activating mutations similar to those described for gastrointestinal stromal tumours were found. phyllodes 54-63 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 12-17 15343505-0 2004 Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. phyllodes 120-129 vascular endothelial growth factor A Homo sapiens 22-56 15343505-7 2004 Assessment of stromal VEGF may be useful as an adjunctive diagnostic criterion in the histologic assessment of malignancy in phyllodes tumors. phyllodes 125-134 vascular endothelial growth factor A Homo sapiens 22-26 15725803-9 2005 The stromal component of all phyllodes tumors was positive for vimentin, whereas all other investigated markers were absent except for focal p63 and CD10 expression in 1 case each. phyllodes 29-38 vimentin Homo sapiens 63-71 15677540-0 2005 Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. phyllodes 53-62 membrane metalloendopeptidase Homo sapiens 8-12 15677540-5 2005 Stromal CD10 expression was positive in one of 33 fibroadenomas, six of 102 benign phyllodes tumours, 16 of 51 borderline malignant phyllodes tumours, and 14 of 28 frankly malignant phyllodes tumours. phyllodes 83-92 membrane metalloendopeptidase Homo sapiens 8-12 15677540-5 2005 Stromal CD10 expression was positive in one of 33 fibroadenomas, six of 102 benign phyllodes tumours, 16 of 51 borderline malignant phyllodes tumours, and 14 of 28 frankly malignant phyllodes tumours. phyllodes 132-141 membrane metalloendopeptidase Homo sapiens 8-12 16168127-2 2005 We studied the expression and prognostic relevance of HIF-1alpha and its downstream targets in phyllodes tumors and fibroadenomas of the breast. phyllodes 95-104 hypoxia inducible factor 1 subunit alpha Homo sapiens 54-64 15522319-0 2004 Perioperative diagnosis of cystosarcoma phyllodes of the breast may be enhanced by MIB-1 index. phyllodes 40-49 MIB E3 ubiquitin protein ligase 1 Homo sapiens 83-88 15044924-0 2004 Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. phyllodes 56-65 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 10-15 15044924-0 2004 Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. phyllodes 56-65 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 17-22 15044924-6 2004 The overall positive rate for c-kit was 29% (52/179) and 17% (17/101), 24% (12/50) and 46% (13/28), respectively, for benign, borderline malignant and frank malignant phyllodes and the differences between all categories were significant (chi2=13.844, P=0.001). phyllodes 167-176 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 30-35 14559983-6 2003 P53 protein expression showed a positive correlation with microvessel density, suggesting possible overlap in the underlying mechanism of these two factors in the pathogenesis of phyllodes tumors. phyllodes 179-188 tumor protein p53 Homo sapiens 0-3 14559983-8 2003 We conclude that microvessel density and p53 are useful as independent criteria in evaluating malignancy in phyllodes tumors. phyllodes 108-117 tumor protein p53 Homo sapiens 41-44 12898599-1 2003 The aim of this study was to assess the expression of IGF-I and IGF-II in phyllodes tumours and fibroadenomas and to see if there is any correlation between nuclear beta-catenin expression and IGF-I and IGF-II expression in these tumours. phyllodes 74-83 insulin like growth factor 1 Homo sapiens 54-59 12898599-1 2003 The aim of this study was to assess the expression of IGF-I and IGF-II in phyllodes tumours and fibroadenomas and to see if there is any correlation between nuclear beta-catenin expression and IGF-I and IGF-II expression in these tumours. phyllodes 74-83 insulin like growth factor 2 Homo sapiens 64-70 12898599-1 2003 The aim of this study was to assess the expression of IGF-I and IGF-II in phyllodes tumours and fibroadenomas and to see if there is any correlation between nuclear beta-catenin expression and IGF-I and IGF-II expression in these tumours. phyllodes 74-83 insulin like growth factor 1 Homo sapiens 64-69 12898599-2 2003 In a previous study, it has been shown that Wnt signalling is important in the pathogenesis of phyllodes tumours of the breast. phyllodes 95-104 Wnt family member 2 Homo sapiens 44-47 12898599-7 2003 In situ hybridization was used to assess IGF-I and IGF-II expression in 23 phyllodes tumours and 16 fibroadenomas. phyllodes 75-84 insulin like growth factor 2 Homo sapiens 51-57 12118111-0 2002 Increased p53 protein expression in malignant mammary phyllodes tumors. phyllodes 54-63 tumor protein p53 Homo sapiens 10-13 11815995-0 2002 Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features. phyllodes 48-57 tumor protein p53 Homo sapiens 20-23 11815995-0 2002 Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features. phyllodes 48-57 erb-b2 receptor tyrosine kinase 2 Homo sapiens 36-44 9584322-5 1998 Our results also indicate a good correlation between the conventional grading of phyllodes tumours based on histological criteria and MIB1 indices. phyllodes 81-90 MIB E3 ubiquitin protein ligase 1 Homo sapiens 134-138 11135048-0 2001 Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast. phyllodes 32-41 CD34 molecule Homo sapiens 14-18 11135048-0 2001 Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast. phyllodes 32-41 BCL2 apoptosis regulator Homo sapiens 23-28 10547570-11 1999 It is concluded that p53 gene status and an accumulation of BAX, both involved in the same apoptosis-controlling pathway, may be of prognostic relevance in phyllodes tumours. phyllodes 156-165 tumor protein p53 Homo sapiens 21-24 10547570-11 1999 It is concluded that p53 gene status and an accumulation of BAX, both involved in the same apoptosis-controlling pathway, may be of prognostic relevance in phyllodes tumours. phyllodes 156-165 BCL2 associated X, apoptosis regulator Homo sapiens 60-63 11070114-4 2000 There was neoplastic stromal cell positivity for PDGFRbeta in almost 50% of phyllodes tumors and for PDGF in 24%. phyllodes 76-85 platelet derived growth factor receptor beta Homo sapiens 49-58 11070114-6 2000 Co-positivity for stromal PDGF and PDGFRbeta was found in 15% of phyllodes tumors, and for epithelial PDGF and stromal PDGFRbeta in 43%. phyllodes 65-74 platelet derived growth factor receptor beta Homo sapiens 35-44 2704424-3 1989 It was found that primary breast carcinomas and cystosarcomas phyllodes contain significantly higher levels of cathepsin B activity than mammary dysplasias; the activity of cathepsin B in cystosarcomas phyllodes was comparable with that in breast carcinomas. phyllodes 62-71 cathepsin B Homo sapiens 111-122 7687354-2 1993 In this study, C-erbB-2 expression was studied immunohistochemically on frozen sections in 63 infiltrating carcinomas, 3 phyllodes tumours, 15 fibroadenomas and 16 cases of fibrocystic disease. phyllodes 121-130 erb-b2 receptor tyrosine kinase 2 Homo sapiens 15-23 33782741-5 2021 KMT2D and SETD2 mutations were present in both the conventional phyllodes tumour and endometriosis-like areas and are also described in endometriosis raising interesting questions about these lesions. phyllodes 64-73 lysine methyltransferase 2D Homo sapiens 0-5 33782741-5 2021 KMT2D and SETD2 mutations were present in both the conventional phyllodes tumour and endometriosis-like areas and are also described in endometriosis raising interesting questions about these lesions. phyllodes 64-73 SET domain containing 2, histone lysine methyltransferase Homo sapiens 10-15 34597441-5 2021 MED12 mutation was identified in 19 primary tumors (12 phyllodes tumors and 7 fibroadenomas) and 17 recurrences (14 phyllodes tumors and three fibroadenomas). phyllodes 55-64 mediator complex subunit 12 Homo sapiens 0-5 34597441-5 2021 MED12 mutation was identified in 19 primary tumors (12 phyllodes tumors and 7 fibroadenomas) and 17 recurrences (14 phyllodes tumors and three fibroadenomas). phyllodes 116-125 mediator complex subunit 12 Homo sapiens 0-5 34597441-8 2021 TERT promoter mutation was identified in 13 primary phyllodes tumors (13/19) and 15 recurrent phyllodes tumors (15/19). phyllodes 52-61 telomerase reverse transcriptase Homo sapiens 0-4 34597441-11 2021 Our findings suggest that recurrent phyllodes tumors may be "true recurrence," and TERT mutant "benign fibroepithelial tumors" should be treated as phyllodes tumors. phyllodes 148-157 telomerase reverse transcriptase Homo sapiens 83-87 2704424-3 1989 It was found that primary breast carcinomas and cystosarcomas phyllodes contain significantly higher levels of cathepsin B activity than mammary dysplasias; the activity of cathepsin B in cystosarcomas phyllodes was comparable with that in breast carcinomas. phyllodes 62-71 cathepsin B Homo sapiens 173-184 2704424-3 1989 It was found that primary breast carcinomas and cystosarcomas phyllodes contain significantly higher levels of cathepsin B activity than mammary dysplasias; the activity of cathepsin B in cystosarcomas phyllodes was comparable with that in breast carcinomas. phyllodes 202-211 cathepsin B Homo sapiens 173-184 2454275-3 1987 Vimentin and desmin were detected in the sarcomatous portion of carcinosarcoma, focally in the stromal component of phyllodes tumors and not always in the stromal sarcomas. phyllodes 116-125 vimentin Homo sapiens 0-8 2454275-3 1987 Vimentin and desmin were detected in the sarcomatous portion of carcinosarcoma, focally in the stromal component of phyllodes tumors and not always in the stromal sarcomas. phyllodes 116-125 desmin Homo sapiens 13-19 193460-0 1977 Progesterone receptor in cystosarcoma phyllodes. phyllodes 38-47 progesterone receptor Homo sapiens 0-21 33863915-2 2021 TERT promoter hotspot mutations and gene amplification are rare in common forms of breast cancer, but present in a subset of phyllodes tumors. phyllodes 125-134 telomerase reverse transcriptase Homo sapiens 0-4 33447858-11 2021 CONCLUSIONS: We encountered a rare case of G-CSF-producing malignant phyllodes tumor of the breast. phyllodes 69-78 colony stimulating factor 3 Homo sapiens 43-48 33026185-7 2021 A marked difference in NGF expression was detected in phyllodes tumors compared to fibroadenomas. phyllodes 54-63 nerve growth factor Homo sapiens 23-26 33026185-8 2021 The maximum NGF expression was observed in phyllodes tissue followed by cancer tissue, and the least expression in fibroadenomas (3-5 times less than in phyllodes; comparable with normal breast tissue). phyllodes 43-52 nerve growth factor Homo sapiens 12-15 33026185-10 2021 This study reports abundant NGF secretion by breast phyllodes, raising the possibility of its potential role in tumor pathogenesis and progression that can be exploited therapeutically. phyllodes 52-61 nerve growth factor Homo sapiens 28-31 33026185-11 2021 Additionally, NGF may be used as a distinct biomarker of phyllodes tumors, for differentiating them from fibroadenomas during histopathology. phyllodes 57-66 nerve growth factor Homo sapiens 14-17 33245988-7 2021 Stromal cells expressed LEF-1 in 100% (16/16 of core TMA) of malignant phyllodes, compared to 73% (16/22) borderline and 27% (13/48) benign tumors. phyllodes 71-80 lymphoid enhancer binding factor 1 Homo sapiens 24-29 33844099-0 2021 SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast. phyllodes 54-63 SET domain containing 2, histone lysine methyltransferase Homo sapiens 0-5 32986365-0 2020 Ki67 and P53 Expression in Relation to Clinicopathological Features in Phyllodes Tumour of the Breast. phyllodes 71-80 tumor protein p53 Homo sapiens 9-12 32857809-0 2020 Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors. phyllodes 45-54 epithelial membrane protein 1 Homo sapiens 14-18 32857809-0 2020 Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors. phyllodes 45-54 epithelial membrane protein 3 Homo sapiens 30-34